<code id='F01D273967'></code><style id='F01D273967'></style>
    • <acronym id='F01D273967'></acronym>
      <center id='F01D273967'><center id='F01D273967'><tfoot id='F01D273967'></tfoot></center><abbr id='F01D273967'><dir id='F01D273967'><tfoot id='F01D273967'></tfoot><noframes id='F01D273967'>

    • <optgroup id='F01D273967'><strike id='F01D273967'><sup id='F01D273967'></sup></strike><code id='F01D273967'></code></optgroup>
        1. <b id='F01D273967'><label id='F01D273967'><select id='F01D273967'><dt id='F01D273967'><span id='F01D273967'></span></dt></select></label></b><u id='F01D273967'></u>
          <i id='F01D273967'><strike id='F01D273967'><tt id='F01D273967'><pre id='F01D273967'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:539
          An AstraZeneca sign at ESMO in Madrid.
          An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

          MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

          On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

          advertisement

          The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          The explosion of genetic testing requires a new approach
          The explosion of genetic testing requires a new approach

          AtechnicianplacesanarraycontainingDNAinformationinascanner.GREGBAKER/AFPviaGettyImagesNewtechnologyh

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          PhRMA lawsuit over Medicare drug price negotiation tossed

          APStockWASHINGTON—AfederaldistrictjudgeonMondaygrantedtheBidenadministration’srequesttodismissalawsu